UBS ASSET MANAGEMENT AMERICAS LLC - SANGAMO THERAPEUTICS INC ownership

SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 195 filers reported holding SANGAMO THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.58 and the average weighting 0.0%.

Quarter-by-quarter ownership
UBS ASSET MANAGEMENT AMERICAS LLC ownership history of SANGAMO THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$268,6860.0%152,6620.0%0.00%
Q1 2023$268,686
-35.9%
152,662
+14.3%
0.00%
Q4 2022$419,359
-99.9%
133,5540.0%0.00%
Q3 2022$654,414,000
+12.2%
133,554
-5.2%
0.00%
Q2 2022$583,019,000
-19.9%
140,826
+12.4%
0.00%
Q1 2022$727,923,000
-18.9%
125,288
+4.7%
0.00%
Q4 2021$897,376,000
+0.3%
119,650
+20.4%
0.00%
Q3 2021$895,117,000
-23.4%
99,347
+1.7%
0.00%
-100.0%
Q2 2021$1,169,038,000
-8.3%
97,664
-4.0%
0.00%0.0%
Q1 2021$1,274,853,000
-91.3%
101,744
-89.2%
0.00%
-85.7%
Q4 2020$14,725,503,000
+105.8%
943,640
+24.6%
0.01%
+75.0%
Q3 2020$7,154,264,000
+6.4%
757,065
+0.9%
0.00%0.0%
Q2 2020$6,724,883,000
+38.4%
750,545
-1.6%
0.00%
+33.3%
Q1 2020$4,858,113,000
-30.7%
762,655
-8.9%
0.00%
-25.0%
Q4 2019$7,005,489,000
-7.7%
836,976
-0.2%
0.00%
-20.0%
Q3 2019$7,591,629,000
-11.8%
838,854
+4.9%
0.01%
-16.7%
Q2 2019$8,610,129,000
+29.1%
799,455
+14.4%
0.01%
+20.0%
Q1 2019$6,668,289,000
-16.9%
698,9820.0%0.01%
-28.6%
Q4 2018$8,024,313,000
-30.1%
698,982
+3.2%
0.01%
-22.2%
Q3 2018$11,481,930,000
+12.2%
677,400
-6.0%
0.01%
+12.5%
Q2 2018$10,232,563,000
-13.2%
720,603
+16.2%
0.01%
-11.1%
Q1 2018$11,781,957,000
+1835.3%
620,103
+1570.4%
0.01%
+800.0%
Q4 2017$608,801,000
+88.8%
37,122
+72.7%
0.00%
Q3 2017$322,470,000
+70.5%
21,4980.0%0.00%
Q2 2017$189,182,000
+253.3%
21,498
+108.8%
0.00%
Q1 2017$53,550,000
+172641.9%
10,2980.0%0.00%
Q4 2016$31,000
-77.2%
10,298
-65.0%
0.00%
Q3 2016$136,000
-20.0%
29,3980.0%0.00%
Q2 2016$170,000
-4.5%
29,3980.0%0.00%
Q1 2016$178,000
-93.8%
29,398
-90.6%
0.00%
-100.0%
Q4 2015$2,855,000
-9.9%
312,665
-44.3%
0.00%0.0%
Q3 2015$3,167,000
-45.0%
561,414
+8.2%
0.00%
-50.0%
Q2 2015$5,757,000
-29.6%
519,096
-0.5%
0.01%
-25.0%
Q1 2015$8,180,000
+2.5%
521,698
-0.6%
0.01%0.0%
Q4 2014$7,980,000
+195.7%
524,698
+109.6%
0.01%
+166.7%
Q3 2014$2,699,000
-26.4%
250,298
+4.2%
0.00%
-25.0%
Q2 2014$3,669,000
-15.6%
240,2980.0%0.00%
-20.0%
Q1 2014$4,345,000
+41.8%
240,298
+8.9%
0.01%
+25.0%
Q4 2013$3,064,000
+33.5%
220,598
+0.7%
0.00%
+33.3%
Q3 2013$2,295,000
+34.2%
218,9980.0%0.00%
+50.0%
Q2 2013$1,710,000218,9980.00%
Other shareholders
SANGAMO THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
Alexandria Capital, LLC 1,003,725$15,663,0001.66%
Golden State Equity Partners 123,817$1,932,0001.33%
Rhenman & Partners Asset Management AB 821,888$12,826,0001.05%
WASATCH ADVISORS LP 10,072,381$157,180,0000.77%
BOGLE INVESTMENT MANAGEMENT L P /DE/ 29,636$462,0000.73%
Ceeto Capital Group, LLC 80,000$1,248,0000.63%
EMC Capital Management 48,992$765,0000.58%
Fort Sheridan Advisors LLC 71,173$1,111,0000.54%
Vanguard Capital Wealth Advisors 34,680$584,0000.54%
Casdin Capital, LLC 1,080,000$16,853,0000.50%
View complete list of SANGAMO THERAPEUTICS INC shareholders